Saruparib: Data from P3 EvoPAR-Prostate01 trial (NCT06120491) for metastatic CSPC post 2026 (AstraZeneca) - Feb 6, 2025 - Q4 & FY2024 Results: Data from P3 EvoPAR-Breast01 trial (NCT06380751) in combination with camizestrant for HR+/HER2-negative advanced breast cancer post 2026
P3 data • Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Prostate Cancer
|